Carteolol Hydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317376

CAS#: 51781-21-6

Description: Carteolol hydrochloride is a beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. Carteolol Hydrochloride is a nonselective beta-adrenoceptor blocking agent for beta-1 and beta-2 receptors with no membrane-stabilizing activity but moderate intrinsic sympathomimetic effects.


Chemical Structure

img
Carteolol Hydrochloride
CAS# 51781-21-6

Theoretical Analysis

MedKoo Cat#: 317376
Name: Carteolol Hydrochloride
CAS#: 51781-21-6
Chemical Formula: C16H25ClN2O3
Exact Mass:
Molecular Weight: 328.83
Elemental Analysis: C, 58.44; H, 7.66; Cl, 10.78; N, 8.52; O, 14.60

Price and Availability

Size Price Availability Quantity
50.0mg USD 240.0 2 Weeks
250.0mg USD 750.0 2 Weeks
Bulk inquiry

Synonym: Carteolol Hydrochloride ; Carteolol HCl; Arteoptic; Cartrol; Mikelan; Abbott-43326; Hydrochloride, Carteolol; Monohydrochloride, Carteolol; OPC 1085; OPC-1085; OPC1085;

IUPAC/Chemical Name: 5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydro-1H-quinolin-2-one;hydrochloride

InChi Key: FYBXRCFPOTXTJF-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H24N2O3.ClH/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13;/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20);1H

SMILES Code: CC(C)(C)NCC(COC1=CC=CC2=C1CCC(=O)N2)O.Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 328.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yao Q, Yu X, Zheng T, Liu H, Yang Y, Yi P. Spectroscopic studies on the
interaction of carteolol hydrochloride and urea-induced bovine serum albumin.
Spectrochim Acta A Mol Biomol Spectrosc. 2013 Sep;113:447-51. doi:
10.1016/j.saa.2013.04.129. Epub 2013 May 16. PubMed PMID: 23747387.

2: Chikama T, Araie M, Nishida T. [Influence on ocular surface and intraocular
pressure of switching from preservative-containing to preservative-free carteolol
hydrochloride ophthalmic solution]. Nippon Ganka Gakkai Zasshi. 2013
May;117(5):419-26. Japanese. PubMed PMID: 23855234.

3: Ishida S, Mochimaru H, Nagai N, Noda K, Ozawa Y. [Effects of carteolol
hydrochloride on experimental choroidal neovascularization]. Nippon Ganka Gakkai
Zasshi. 2011 Apr;115(4):355-61. Japanese. PubMed PMID: 21598603.

4: Kawase K, Yamamoto T, Muramatsu T, Ono J, Nakajima T, Matsuhisa A, Sugiura T,
Migita M, Ishikawa Y. [Long-acting carteolol hydrochloride 2% ophthalmic solution
phase IV study--investigation of the effectiveness, safety and plasma
concentration]. Nippon Ganka Gakkai Zasshi. 2010 Nov;114(11):976-82. Japanese.
PubMed PMID: 21141077.

5: Kaji Y, Kiuchi T, Oshika T. Carteolol hydrochloride suppresses the generation
of reactive oxygen species and rescues cell death after ultraviolet irradiation
of cultured lens epithelial cells. Open Ophthalmol J. 2010 Oct 12;4:60-5. doi:
10.2174/1874364101004010060. PubMed PMID: 21283534; PubMed Central PMCID:
PMC3031156.

6: Nakamoto K, Yasuda N. Effect of carteolol hydrochloride on 24-hour variation
of intraocular pressure in normal-tension glaucoma. Jpn J Ophthalmol. 2010
Mar;54(2):140-3. doi: 10.1007/s10384-009-0780-6. Epub 2010 Apr 18. PubMed PMID:
20401563.

7: Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A. Carteolol hydrochloride
protects human corneal epithelial cells from UVB-induced damage in vitro. Cornea.
2005 Mar;24(2):213-20. PubMed PMID: 15725891.

8: Kawai K, Kuwahara K, Oizumi N, Kitagaki H, Fujisawa S. Effects of carteolol
hydrochloride on the in vitro production of LPS-induced proinflammatory cytokines
by murine macrophage. J Ocul Pharmacol Ther. 2004 Jun;20(3):237-45. PubMed PMID:
15279728.

9: Isawa S, Murasaki M, Miura S, Yoshioka M, Uchiumi M, Kumagai Y, Aoki S,
Hisazumi H, Kudo S. Pharmacokinetic and pharmacodynamic interactions among
haloperidol, carteolol hydrochloride and biperiden hydrochloride. Nihon Shinkei
Seishin Yakurigaku Zasshi. 1999 Jul;19(3):111-8. PubMed PMID: 10495985.

10: Kober G, Veidt J, Mikludy R, Kaltenbach M. [Heart rate behavior and the
ischemic ST-segment under carteolol hydrochloride. Dose-response relationship and
duration of effect]. Arzneimittelforschung. 1983;33(2a):313-7. German. PubMed
PMID: 6682323.

11: El-Kamel A, Al-Dosari H, Al-Jenoobi F. Environmentally responsive ophthalmic
gel formulation of carteolol hydrochloride. Drug Deliv. 2006 Jan-Feb;13(1):55-9.
PubMed PMID: 16401594.

12: Stewart WC, Cohen JS, Netland PA, Weiss H, Nussbaum LL. Efficacy of carteolol
hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular
pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Am
J Ophthalmol. 1997 Oct;124(4):498-505. PubMed PMID: 9323940.

13: Kudo S, Umehara K, Abe Y, Furukawa M, Odomi M. Intracerebral penetration of
carteolol hydrochloride in rats. Psychopharmacology (Berl). 1997
Jun;131(4):388-93. PubMed PMID: 9226741.

14: Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL. Cardiovascular
effects of topical carteolol hydrochloride and timolol maleate in patients with
ocular hypertension and primary open-angle glaucoma. Night Study Group. Am J
Ophthalmol. 1997 Apr;123(4):465-77. PubMed PMID: 9124243.

15: Kikuchi T, Uwahodo Y, Tottori K, Nakai M, Morita S. The attenuating effect of
carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced
catalepsy in rats. Psychopharmacology (Berl). 1997 May;131(2):108-14. PubMed
PMID: 9201797.

16: van Husen H. [1% carteolol hydrochloride eyedrops: long-term experience in
the treatment of chronic open-angle glaucoma]. Klin Monbl Augenheilkd. 1986
Dec;189(6):491-5. German. PubMed PMID: 3550260.

17: Mizuki K, Yamazaki Y. [Effect of carteolol hydrochloride on ocular blood flow
dynamics in normal human eyes]. Nippon Ganka Gakkai Zasshi. 2000
Apr;104(4):226-31. Japanese. PubMed PMID: 10793541.

18: Mirza GE, Karaküçük S, Temel E. Comparison of the effects of 0.5% timolol
maleate, 2% carteolol hydrochloride, and 0.3% metipranolol on intraocular
pressure and perimetry findings and evaluation of their ocular and systemic
effects. J Glaucoma. 2000 Feb;9(1):45-50. PubMed PMID: 10708231.

19: Tamagawa M, Numoto T, Tanaka N, Nishino H. Reproduction study of carteolol
hydrochloride in mice. Part 2. Peri -and postnatal toxicity. J Toxicol Sci. 1979
Feb;4(1):59-77. PubMed PMID: 480406.

20: Tanaka N, Shingai F, Tamagawa M, Nakatsu I. Reproduction study of carteolol
hydrochloride in mice. Part I. Fertility and reproductive performance. J Toxicol
Sci. 1979 Feb;4(1):47-58. PubMed PMID: 480405.